Intensify Antihypertensive Therapy by Increasing Lotrel Dose or Adding a Third Agent
For this 65-year-old patient with SBP in the 150s on Lotrel 5/10 mg, you should intensify therapy by either increasing the Lotrel dose or adding a third antihypertensive medication to achieve better blood pressure control.
Rationale Based on Current Guidelines
The 2017 ACC/AHA guidelines 1 classify this patient as having Stage 2 hypertension (SBP ≥140 mm Hg) and recommend combination therapy with two agents of different classes, which this patient is already receiving. However, the current regimen is clearly inadequate given the persistent SBP in the 150s.
Key Considerations for Target Blood Pressure
There is important divergence in guidelines for patients over 60:
- ACC/AHA 2017 1: Recommends target SBP <130 mm Hg for most adults, including those ≥65 years
- ACP/AAFP 2017 2: Recommends target SBP <150 mm Hg for adults ≥60 years (strong recommendation), with consideration for <140 mm Hg in high cardiovascular risk patients (weak recommendation)
Given that this patient's SBP is in the 150s, they are above target by BOTH guidelines, making intensification clearly indicated regardless of which guideline you follow.
Specific Treatment Options
Option 1: Increase Lotrel Dose (Preferred Initial Step)
Lotrel contains benazepril (ACE inhibitor) and amlodipine (calcium channel blocker). Current dose is 5/10 mg, which is relatively low:
Recommended action: Increase to Lotrel 10/10 mg or 10/20 mg, as the benazepril component is at the lower end of the therapeutic range 3.
Option 2: Add a Thiazide-Like Diuretic
If dose escalation is insufficient or not tolerated, add:
- Chlorthalidone 12.5-25 mg daily (preferred over hydrochlorothiazide based on prolonged half-life and proven CVD reduction) 1
- This creates a three-drug regimen: ACE inhibitor + CCB + thiazide-like diuretic
The combination of lisinopril (similar ACE inhibitor) with hydrochlorothiazide has demonstrated effectiveness in elderly patients with systolic hypertension 4.
Important Safety Monitoring
Before intensifying therapy, verify:
- Renal function: Monitor creatinine and potassium, especially when increasing ACE inhibitor dose 3
- Orthostatic vital signs: Assess for symptomatic hypotension risk, particularly in elderly patients 3
- Medication adherence: Confirm the patient is actually taking the current regimen consistently
- Accurate BP measurement: Consider ambulatory or home BP monitoring to rule out white coat hypertension 2
Common Pitfalls to Avoid
- Don't accept SBP in the 150s as adequate - this patient needs better control regardless of age
- Don't add potassium-sparing diuretics without careful monitoring, as ACE inhibitors already increase hyperkalemia risk 1
- Monitor for pedal edema with amlodipine dose increases (dose-related, more common in women) 1
- Watch for cough with benazepril escalation (common ACE inhibitor side effect) 2
Follow-Up Timeline
Reassess BP in 1 month after medication adjustment 1. This is the recommended interval for patients with Stage 2 hypertension on combination therapy requiring intensification.
Cardiovascular Risk Assessment
Consider calculating 10-year ASCVD risk to determine if this patient falls into the high-risk category (≥10%), which would further support targeting SBP <130-140 mm Hg rather than accepting <150 mm Hg 1, 2. Patients with history of stroke/TIA or established cardiovascular disease warrant more aggressive targets of <140 mm Hg 2.